Evidence map›Paper›PMID 39050711›Full record

ArticleTurkish journal of biology = Turk biyoloji dergisi2024

PEtOx-DOPE nanoliposomes functionalized with peptide 563 in targeted

Ayca Ece Nezir, Zeynep Büşra Bolat, Ongun Mehmet Saka, Itır Ebru Zemheri, Sevgi Gülyüz, Umut Uğur Özköse, Özgür Yilmaz, Asuman Bozkir, Fikrettin Şahin, Dilek Telci

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Turkish journal of biology = Turk biyoloji dergisi, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ayca Ece NezirDepartment of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, İstanbul, Turkiye.ORCID https://orcid.org/0000-0001-8229-1865
Zeynep Büşra BolatDepartment of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, İstanbul, Turkiye.ORCID https://orcid.org/0000-0002-9216-6336
Ongun Mehmet SakaDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Ankara University, Ankara, Turkiye.ORCID https://orcid.org/0000-0002-8726-6391
Itır Ebru ZemheriDepartment of Pathology, Ümraniye Training and Research Hospital, University of Health Sciences, İstanbul, Turkiye.ORCID https://orcid.org/0000-0003-0247-0332
Sevgi GülyüzMaterials Technologies, Marmara Research Center, TÜBİTAK, Kocaeli, Turkiye.ORCID https://orcid.org/0000-0002-2576-3085
Umut Uğur ÖzköseMaterials Technologies, Marmara Research Center, TÜBİTAK, Kocaeli, Turkiye.ORCID https://orcid.org/0000-0003-4807-6322
Özgür YilmazMaterials Technologies, Marmara Research Center, TÜBİTAK, Kocaeli, Turkiye.ORCID https://orcid.org/0000-0003-3892-2775
Asuman BozkirDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Ankara University, Ankara, Turkiye.ORCID https://orcid.org/0000-0002-2782-3280
Fikrettin ŞahinDepartment of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, İstanbul, Turkiye.ORCID https://orcid.org/0000-0003-1503-5567
Dilek TelciDepartment of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, İstanbul, Turkiye.ORCID https://orcid.org/0000-0002-2793-6533

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Nanocarrier-based systems have cultivated significant improvements in prostate cancer therapy. However, the efforts are still limited in clinical applicability, and more research is required for the development of effective strategies. Here, we describe a novel nanoliposomal system for targeted apoptotic gene delivery to prostate cancer. Methods: Poly (2-ethyl-2-oxazoline) (PEtOx) dioleoyl phosphatidylethanolamine (DOPE) nanoliposomes were conjugated with the prostate-specific membrane antigen (PSMA)-targeting peptide GRFLTGGTGRLLRIS (P563) and loaded with Results: Conclusion: We suggest that P563-PEtOx-DOPE-BikDDA nanoliposomes can serve as prominent gene carriers against prostate cancer.

Indexed as

BikDDAliposomepeptide 563poly(2-ethyl-2-oxazoline)Prostate cancertargeted gene therapy

Identifiers

PMID39050711
PMCPMC11265899

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.